3D Printed Drugs Market by Technology (Direct-Write, Fused Deposition Modelling, Inkjet Printing), Dose Form (Capsule, Nanoparticles, Tablet), Application, End-User - Global Forecast 2024-2030

3D Printed Drugs Market by Technology (Direct-Write, Fused Deposition Modelling, Inkjet Printing), Dose Form (Capsule, Nanoparticles, Tablet), Application, End-User - Global Forecast 2024-2030

The 3D Printed Drugs Market size was estimated at USD 292.72 million in 2023 and expected to reach USD 331.22 million in 2024, at a CAGR 14.26% to reach USD 744.29 million by 2030.

3D printed drugs refer to the emerging use of 3D printing technology to create pharmaceutical products with improved drug delivery mechanisms. 3D printing of drugs enables personalization, precision, and cost-efficiency in drug manufacturing. The proliferation of 3D printed drugs is transforming the pharmaceutical industry, enabling the design of medications in any desired shape, size, dose, and delivery rate, delivering personalized healthcare for patients. Increased drug discovery and development activities and an inclination towards a personalized medicines approach are raising the need for advanced drug manufacturing techniques such as 3D printing of drugs. However, the high upfront cost of 3D printing technology may adversely impact the production of 3D printed drugs. Moreover, technological advancements in 3D printing technology are expected to enhance drug production efficiency, which is anticipated to expand its use for the development of drugs.

Regional Insights

The Americas have a significant landscape in the 3D-printed drugs market owing to progressive medical research and development, the robust pharmaceutical industry, and the presence of key 3D-printed drug manufacturers. Rising technological advancements and enhanced healthcare infrastructure further advance the market landscape in the region. Europe has observed a significant market for 3D printed drugs, driven by a rising geriatric population, initiatives towards personalized medicine, supportive governmental regulations, and funding activities from government and key manufacturers. In the Middle East & Africa, increasing investments in technological adoption and healthcare infrastructure enhancement contribute to market growth. The Asia-Pacific region is witnessing an emerging stage in the 3D printed drugs market and shows significant growth potential driven by factors such as rapid urbanization, innovations in healthcare technologies, increasing healthcare expenditures, and a rising elderly population requiring customized medication.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the 3D Printed Drugs Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

• Surge in demand for instantaneous soluble drugs
• Growing adoption of personalized drugs and the production of combination medicine
• Extensive use of 3D printed technology for manufacturing cancer drugs

Market Restraints

• Material limitations associated with manufacturing of 3D printed drugs

Market Opportunities

• Constant technological developments in 3D printing technique
• Significant investments for manufacturing of 3D printed pharmaceuticals

Market Challenges

• Complexities in manufacturing of 3D printed drugs

Market Segmentation Analysis

• Technology: Direct-write technology provides personalized and effective medication solutions
• Dose Form: Potential adoption of 3D printed drugs in the form of capsule
• Application: Proliferating use for manufacturing of neurology drugs
• End-User: Significant penetration of 3D printed drugs in clinics & hospitals

Market Disruption Analysis

• Porter’s Five Forces Analysis
• Value Chain & Critical Path Analysis
• Pricing Analysis
• Technology Analysis
• Patent Analysis
• Trade Analysis
• Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the 3D Printed Drugs Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the 3D Printed Drugs Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

CurifyLabs Launches 3D Printing Solution For Personalised Medicine

CurifyLabs introduced GMP (good manufacturing practice) produced Pharma Inks for 3D printable medicines, facilitating a novel solution for producing patient-tailored and personalized medicines in pharmacies and hospitals. CurifyLabs’ Pharma Kit, including automated 3D printing technology and printable pharmaceutical inks, allows wider adoption of personalized medicine, resulting in better future care for patients.

Cellink And Carcinotech Partner To Transform Cancer Drug Development With 3d Bioprinting

Carcinotech and 3D bioprinting firm CELLINK collaborated to accelerate cancer drug development with 3D bioprinted tumor models. The partnership focuses on the development and commercialization of cutting-edge protocols for the fabrication of 3D bioprinted tumor models using cancer cell lines. These models are designed to significantly improve accuracy and speed up drug development processes, ultimately reducing development costs and enhancing research output.

Triastek Receives FDA IND Clearance for 3D Printed Medicine for the Treatment of Ulcerative Colitis

Triastek, Inc. received U.S. FDA clearance for its investigational new drug (IND) application for clinical studies of the T21, 3D printed medicine related to potential treatment for ulcerative colitis. T21 is a potential treatment capable of colon-targeted drug delivery. With a unique 3D dosage form design, T21 can reach the targeted colon segment of the GI tract, thus permitting the use of a lower drug dose than the reference-listed drug, which provides systemic exposure.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the 3D Printed Drugs Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the 3D Printed Drugs Market, highlighting leading vendors and their innovative profiles. These include 3D Systems, Inc., 3DR HOLDINGS, Anatomics Pty Ltd, Aprecia Pharmaceuticals, LLC, AstraZeneca plc, BioDuro, LLC, Biomedical Modeling Inc., Cycle Pharmaceuticals, Cyfuse Biomedical K.K., EnvisionTEC GmbH, FabRx Ltd., General Electric Company, GlaxoSmithKline Plc, Materialise NV, Merck KGaA, Organovo Holdings Inc., Proto Labs Inc., Renishaw PLC, Rokit Healthcare Inc., Siemens AG, Stratasys Ltd., Triastek, Inc., TVASTA, Yissum, and Zortrax S.A..

Market Segmentation & Coverage

This research report categorizes the 3D Printed Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Technology
• Direct-Write
• Fused Deposition Modelling
• Inkjet Printing
• Powder Bed Printing
• Stereolithography
• Zip Dose
• Dose Form
• Capsule
• Nanoparticles
• Tablet
• Application
• Dental
• Neurology
• Orthopedic
• End-User
• Clinics & Hospitals
• Research Laboratories
• Speciality Clinics
• Region
• Americas
• Argentina
• Brazil
• Canada
• Mexico
• United States
• California
• Florida
• Illinois
• New York
• Ohio
• Pennsylvania
• Texas
• Asia-Pacific
• Australia
• China
• India
• Indonesia
• Japan
• Malaysia
• Philippines
• Singapore
• South Korea
• Taiwan
• Thailand
• Vietnam
• Europe, Middle East & Africa
• Denmark
• Egypt
• Finland
• France
• Germany
• Israel
• Italy
• Netherlands
• Nigeria
• Norway
• Poland
• Qatar
• Russia
• Saudi Arabia
• South Africa
• Spain
• Sweden
• Switzerland
• Turkey
• United Arab Emirates
• United Kingdom

Please Note: PDF & Excel + Online Access - 1 Year